Rhiannon Jenkinson, Director of Science at Charles River, discusses modeling the immune response.
Rhiannon J. (00:06): So Charles River can help you define your target engagement all the way through from cell biology, through PD models, through disease models, and then on through into the clinic, by defining the effect of a therapeutic on the same target all the way through the discovery process. This enables this information to be integrated across multiple cell types and assay systems. This empowers you to make informed decisions around refining and optimizing your therapeutic, and can ultimately inform go/no-go decisions. Rhiannon J. (00:40): When considering how we should best model the immune response, then the disease setting must first be taken into consideration. So for example, for a therapeutic that's going into the immune oncology space, it's important that we have a system which is suboptimal, such that a therapeutic and enhance activation of the immune response. The converse is true when we're considering a therapeutic which is going into the autoimmune space. Rhiannon J. (01:08): So in this situation where the response is normally unregulated, or is being driven chronically, we need to have a system where the immune system is activated optimally, such that we can dial it back. In addition, to being able to dial back the immune response, the aim of a lot of therapeutics within the autoimmune space is to drive regulation and long-term regulation of the immune response. Rhiannon J. (01:35): So at Charles River, we can model this situation by using cell systems where we can look at differentiation of T cells for example, and look to see whether a therapeutic's driving these cells into a regulatory phenotype. We can also look at the function of naturally occurring T-regs to see whether a therapeutic is able to enhance their function and drive more regulation. Rhiannon J. (02:00): So our integrated immunology expertise across the therapeutic areas allows us to help you select the best model to determine whether your therapeutic is hitting its target and with the expected outcomes.